Skip to content

Application Study of Adaptive Radiotherapy for Cardiac Protection in Thoracic Malignancies

Application Study of Adaptive Radiotherapy for Cardiac Protection in Thoracic Malignancies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094837
Enrollment
Unknown
Registered
2024-12-29
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with histologically confirmed thoracic malignant tumors such as lung cancer, esophageal cancer, and breast cancer; 2. Age 18 to 70 years old; 3. Patients who plan to undergo radical concurrent chemoradiotherapy or radiotherapy; 4. KPS score >=70 or ECOG 0-2; 5. Leukocyte >=4.0×10^9/L, neutrophil >=2.0×10^9/L, platelet >=100×10^9/L, hemoglobin >=100g/L, normal liver and kidney function, and pulmonary function FEV1>=50%.

Exclusion criteria

Exclusion criteria: 1. Presence of distant metastatic organs; 2. Malignant pleural effusion; 3. History of other malignant tumors; 4. Combined with serious underlying diseases; 5. Patients with mental disorders, pregnancy, and lactation; 6. Presence of contraindications to radiotherapy.

Design outcomes

Primary

MeasureTime frame
Major Adverse Cardiovascular Events,MACE;Overall Survival, OS;

Secondary

MeasureTime frame
PFS (Progression-Free-Survival);Radiationpneumonia, RP;Radiation esophagitis, RE;Quality of life assessment;

Countries

China

Contacts

Public ContactWu Chengjun

Xuzhou Central Hospital

wy052070@163.com+86 15365886295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026